Of these effectors, MCP-1 likely concentrates monocytes and neutrophils at the tumor site, provoking an inflammatory response [17]; IL-6 and IL-12, which are responsible for activation of T- and B-cells, would facilitate production of tumor cell-specific antibodies [18,19]. The gene discussed is CCL2; the disease is neoplasm.